These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34992121)

  • 1. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy.
    Kang J; Cairns J
    BMJ Open; 2022 Jan; 12(1):e055985. PubMed ID: 34992121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011-2021.
    Kang J; Cairns J
    BMJ Open; 2024 Mar; 14(3):e077297. PubMed ID: 38485485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
    Kang J; Cairns J
    BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
    Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
    Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
    Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
    Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
    Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
    BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of quality of data submitted for NICE technology appraisals over two decades.
    Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
    BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study.
    Mpofu P; Kent S; Jónsson P; Pittell H; Groves B; Altomare I; Copeland A; Baxi S; Bargo D; Sujenthiran A; Adamson B
    BMJ Open; 2023 Oct; 13(10):e074559. PubMed ID: 37848301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the health technology assessment of complex interventions: a protocol for a scoping review.
    Baghbanian A; Merlin T; Carter D; Wang S
    BMJ Open; 2020 Nov; 10(11):e039263. PubMed ID: 33257482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
    Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
    Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
    Leahy TP; Ramagopalan S; Sammon C
    BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
    Osipenko L
    BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.